<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03708367</url>
  </required_header>
  <id_info>
    <org_study_id>DRYE-102-SELF</org_study_id>
    <nct_id>NCT03708367</nct_id>
  </id_info>
  <brief_title>A Post-Market Evaluation of LipiFlow Treatment in Cataract Surgery Practice</brief_title>
  <official_title>A Post-Market Evaluation of LipiFlow Treatment in Cataract Surgery Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Surgical Vision, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Surgical Vision, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a post-market, prospective, randomized, multi-center, bilateral, open-label,&#xD;
      cross-over, comparative clinical study. Study group will undergo preoperative LipiFlow&#xD;
      treatment and Control group will not receive preoperative LipiFlow treatment. Three months&#xD;
      postoperatively, both groups will be evaluated for clinical outcomes and the Control group&#xD;
      will receive LipiFlow treatment as the cross-over group. The Control group will be evaluated&#xD;
      at 4 months postoperative for clinical outcomes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 16, 2018</start_date>
  <completion_date type="Actual">January 13, 2020</completion_date>
  <primary_completion_date type="Actual">January 13, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Monocular UCDVA (Uncorrected Distance Visual Acuity)</measure>
    <time_frame>3 months Postoperative</time_frame>
    <description>Uncorrected Distance Visual Acuity was measured for the Study and Control groups at the 3-month visit using the Clinical Trial Suite (M&amp;S Technologies) at 4.0 meters under photopic conditions (~85 cd/m2).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Precision (Standard Deviation) of Preoperative Keratometric Measurements</measure>
    <time_frame>2-4 weeks after first Pre-operative visit</time_frame>
    <description>Biometry testing was done pre-operatively</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Precision of Axial Length (AL) and Anterior Chamber Depth (ACD)</measure>
    <time_frame>2-4 weeks after first Pre-operative visit</time_frame>
    <description>Biometry testing was done pre-operatively</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Refractive Predictability</measure>
    <time_frame>Difference between Baseline visit and Postoperative visit at 10-14 weeks after cataract surgery on the second eye.</time_frame>
    <description>Percentage of eyes with achieved manifest refractive spherical equivalence (MRSE) within +/- 0.50 D and +/- 1.00 D.&#xD;
Achieved MRSE for each eye is defined as postoperative MRSE minus targeted MRSE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Bothersome Ocular Symptoms</measure>
    <time_frame>3 months postoperative</time_frame>
    <description>Patient-Reported Visual Symptom Questionnaire (PRVSQ) Rating Results at 3 months postoperative</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change in Total Meibomian Gland Score From Baseline to 1 Month Postoperative</measure>
    <time_frame>Preoperative Visit (Baseline) and Postoperative Visit between 30-60 days after cataract surgery on the second eye.</time_frame>
    <description>Total Meibomian Gland Score: Fifteen Meibomian Glands (five temporally, centrally and nasally) in the lower eye are assessed on a scale of 0 - 3 (0 - No secretion, 1 - Inspissated (toothpaste consistency), 2 - Colored/cloudy liquid secretion or 3 - Clear liquid oil secretion). The sum of all 15 glands constitute the total meibomian gland secretion score (range 0-45).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">117</enrollment>
  <condition>Cataracts</condition>
  <condition>Meibomian Gland Dysfunction (MGD)</condition>
  <arm_group>
    <arm_group_label>Study Group: LipiFlow Treatment at PreOp</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study subjects that meet all inclusion and exclusion criteria will be randomized to receive LipiFlow Thermal Pulsation System treatment at preoperative visit before bilateral implantation with commercially-available Symfony Intraocular Lens</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Study subjects that meet all inclusion and exclusion criteria will be randomized to not receive the LipiFlow Thermal Pulsation System treatment at a preoperative visit before bilaterally implanted with the commercially available Symfony Intraocular Lens. Control Group will receive LipiFlow treatment as cross-over group at 3 months postoperative visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LipiFlow Thermal Pulsation System</intervention_name>
    <description>Treatment at preoperative visit for study group</description>
    <arm_group_label>Study Group: LipiFlow Treatment at PreOp</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LipiFlow Thermal Pulsation System</intervention_name>
    <description>Treatment at 3 month visit as the cross-over group</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (all criteria apply to each study eye):&#xD;
&#xD;
          -  Minimum 22 years of age.&#xD;
&#xD;
          -  Bilateral cataracts for which phacoemulsification extraction and implantation with&#xD;
             Symfony IOLs have been planned.&#xD;
&#xD;
          -  Evidence of Meibomian Gland Dysfunction (MGD) in both eyes based on assessment of&#xD;
             meibomian glands of the lower eyelid&#xD;
&#xD;
          -  None to moderate dry eye symptoms with questionnaire&#xD;
&#xD;
          -  Clear intraocular media other than cataract in each eye.&#xD;
&#xD;
          -  Availability, willingness, ability and sufficient cognitive awareness to comply with&#xD;
             the study protocol including: randomization; examination procedures; completion of&#xD;
             planned bilateral cataract surgeries; compliance with no use of other MGD or dry eye&#xD;
             treatments.&#xD;
&#xD;
          -  Ability to understand, read and write English to consent to study participation and&#xD;
             complete study questionnaires.&#xD;
&#xD;
          -  Willingness to sign informed consent and HIPAA authorization or equivalent&#xD;
             documentation necessary to comply with applicable privacy laws pertaining to medical&#xD;
             treatment in the governing country.&#xD;
&#xD;
        Exclusion Criteria (all criteria apply to each study eye):&#xD;
&#xD;
          -  Any medical finding that would predictably result in a postoperative best corrected&#xD;
             distance visual acuity worse than 20/30 in either eye.&#xD;
&#xD;
          -  Use of systemic or ocular medications that, in the opinion of the investigator, may&#xD;
             affect vision or impact pupil dilation or iris structure.&#xD;
&#xD;
          -  Irregular corneal astigmatism.&#xD;
&#xD;
          -  Any clinically-significant corneal pathology / abnormality other than regular corneal&#xD;
             astigmatism.&#xD;
&#xD;
          -  Any clinically-significant pupil abnormalities.&#xD;
&#xD;
          -  Subjects with conditions associated with increased risk of zonular rupture.&#xD;
&#xD;
          -  Unwillingness or inability to stop wearing contact lens at least two weeks prior to&#xD;
             the baseline visit.&#xD;
&#xD;
          -  Known ocular disease or pathology that, in the opinion of the investigator, may affect&#xD;
             visual acuity or require surgical intervention during the study.&#xD;
&#xD;
          -  Systemic disease condition that causes dry eye.&#xD;
&#xD;
          -  Unwillingness or inability to abstain from the use of systemic medications known to&#xD;
             cause dryness for the study duration. Subjects must have discontinued these&#xD;
             medications for at least 1 month prior to Preoperative Visit.&#xD;
&#xD;
          -  Unwillingness or inability to abstain from the use of systemic antihistamines.&#xD;
&#xD;
          -  Unwillingness or inability to abstain from use of prescription medications for&#xD;
             treatment of MGD or dry eye. Subject must have dicontinued using prescription&#xD;
             medications for MGD or dry eye at least 1 month prior to baseline preoperative visit&#xD;
             #1 measurements.&#xD;
&#xD;
          -  Any of the following ocular (eye or eyelid) conditions in either eye within 3 months&#xD;
             prior to the LipiFlow treatment visit:&#xD;
&#xD;
               -  Prior intraocular, oculoplastic, corneal or refractive surgery procedure (LASIK,&#xD;
                  LASEK, RK, PRK, etc.).&#xD;
&#xD;
               -  Ocular trauma.&#xD;
&#xD;
               -  Ocular Herpes simplex or Herpes zoster (eye or eyelid) infection.&#xD;
&#xD;
               -  History of recurrent ocular inflammation.&#xD;
&#xD;
               -  Punctal plug insertion or punctal occlusion.&#xD;
&#xD;
          -  Any of the following active ocular (eye or eyelid) conditions in either eye at the&#xD;
             baseline Preoperative Visit #1 measurements:&#xD;
&#xD;
               -  Ocular infection.&#xD;
&#xD;
               -  Ocular inflammation.&#xD;
&#xD;
               -  Moderate to severe (Grade 2-4) allergic, vernal or giant papillary conjunctivitis&#xD;
&#xD;
               -  Severe (Grade 3 or 4) inflammation of the eyelid.&#xD;
&#xD;
               -  Eyelid abnormalities that affect lid function.&#xD;
&#xD;
               -  Ocular surface abnormality that may compromise corneal integrity.&#xD;
&#xD;
          -  Concurrent participation or participation within 30 days prior to study visit in any&#xD;
             other clinical trial.&#xD;
&#xD;
          -  Planned monovision correction.&#xD;
&#xD;
          -  Patient is pregnant, plans to become pregnant, is lactating or has another condition&#xD;
             associated with the fluctuation of hormones that could lead to refractive changes.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Priya Janakiraman, OD</last_name>
    <role>Study Director</role>
    <affiliation>Johnson &amp; Johnson Surgical Vision, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Empire Eye &amp; Laser Center, Inc.</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Doctors of Washington</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Matossian Eye Associates</name>
      <address>
        <city>Pennington</city>
        <state>New Jersey</state>
        <zip>08534</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JW Eye Associates, P.A.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Eye &amp; Laser Center, P.A.</name>
      <address>
        <city>Hurst</city>
        <state>Texas</state>
        <zip>76054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 8, 2018</study_first_submitted>
  <study_first_submitted_qc>October 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2018</study_first_posted>
  <results_first_submitted>January 8, 2021</results_first_submitted>
  <results_first_submitted_qc>April 1, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 27, 2021</results_first_posted>
  <last_update_submitted>April 1, 2021</last_update_submitted>
  <last_update_submitted_qc>April 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Meibomian Gland Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 19, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT03708367/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 16, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT03708367/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>All study subjects enrolled from the normal surgical cataract population with bilateral mild to moderate Meibomian Gland Dysfunction, scheduled for bilateral cataract surgeries with Symfony Intraocular Lens implantation, at 5 sites in the U.S.A. 143 Subjects were consented, 26 screen-failed and 117 were randomized and bilaterally implanted. 115 evaluable subjects completed the study (58 in the study group and 57 in the Control Group).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Study Group</title>
          <description>LipiFlow treatment at Pre-operative</description>
        </group>
        <group group_id="P2">
          <title>Control Group</title>
          <description>LipiFlow treatment following 3-month visit</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All eyes that are randomized and implanted</population>
      <group_list>
        <group group_id="B1">
          <title>Study Group</title>
          <description>LipiFlow treatment at Pre-operative</description>
        </group>
        <group group_id="B2">
          <title>Control Group</title>
          <description>LipiFlow treatment following 3-month visit</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="59"/>
            <count group_id="B2" value="58"/>
            <count group_id="B3" value="117"/>
          </count_list>
        </analyzed>
        <analyzed>
          <units>Eyes</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="117"/>
            <count group_id="B2" value="115"/>
            <count group_id="B3" value="232"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <title>30-39 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40-49 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50-59 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60-69 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=70 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="112"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <title>Asian (Including Indian)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Monocular UCDVA (Uncorrected Distance Visual Acuity)</title>
        <description>Uncorrected Distance Visual Acuity was measured for the Study and Control groups at the 3-month visit using the Clinical Trial Suite (M&amp;S Technologies) at 4.0 meters under photopic conditions (~85 cd/m2).</description>
        <time_frame>3 months Postoperative</time_frame>
        <population>Results from both eyes from all randomized subjects were included. Not all subjects completed all tests.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Group</title>
            <description>LipiFlow treatment at Pre-operative</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>LipiFlow treatment following 3-month visit</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Monocular UCDVA (Uncorrected Distance Visual Acuity)</title>
          <description>Uncorrected Distance Visual Acuity was measured for the Study and Control groups at the 3-month visit using the Clinical Trial Suite (M&amp;S Technologies) at 4.0 meters under photopic conditions (~85 cd/m2).</description>
          <population>Results from both eyes from all randomized subjects were included. Not all subjects completed all tests.</population>
          <units>LogMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.15"/>
                    <measurement group_id="O2" value="0.07" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Precision (Standard Deviation) of Preoperative Keratometric Measurements</title>
        <description>Biometry testing was done pre-operatively</description>
        <time_frame>2-4 weeks after first Pre-operative visit</time_frame>
        <population>Results from both eyes from all randomized subjects were included. Not all subjects completed all tests.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Group</title>
            <description>LipiFlow treatment at Pre-operative</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>LipiFlow treatment following 3-month visit</description>
          </group>
        </group_list>
        <measure>
          <title>Precision (Standard Deviation) of Preoperative Keratometric Measurements</title>
          <description>Biometry testing was done pre-operatively</description>
          <population>Results from both eyes from all randomized subjects were included. Not all subjects completed all tests.</population>
          <units>diopter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Precision of Keratometry 1 (K1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.09"/>
                    <measurement group_id="O2" value="-0.01" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Precision of Keratometry 2 (K2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.09"/>
                    <measurement group_id="O2" value="0.0" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Precision of Axial Length (AL) and Anterior Chamber Depth (ACD)</title>
        <description>Biometry testing was done pre-operatively</description>
        <time_frame>2-4 weeks after first Pre-operative visit</time_frame>
        <population>Results from both eyes from all randomized subjects were included. Not all subjects completed all tests.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Group</title>
            <description>LipiFlow treatment at Pre-operative</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>LipiFlow treatment following 3-month visit</description>
          </group>
        </group_list>
        <measure>
          <title>Precision of Axial Length (AL) and Anterior Chamber Depth (ACD)</title>
          <description>Biometry testing was done pre-operatively</description>
          <population>Results from both eyes from all randomized subjects were included. Not all subjects completed all tests.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Precision of Axial Length (AL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.02"/>
                    <measurement group_id="O2" value="0.0" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Precision of Anterior Chamber Depth (ACD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.01"/>
                    <measurement group_id="O2" value="0.0" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate of Refractive Predictability</title>
        <description>Percentage of eyes with achieved manifest refractive spherical equivalence (MRSE) within +/- 0.50 D and +/- 1.00 D.&#xD;
Achieved MRSE for each eye is defined as postoperative MRSE minus targeted MRSE.</description>
        <time_frame>Difference between Baseline visit and Postoperative visit at 10-14 weeks after cataract surgery on the second eye.</time_frame>
        <population>Results from both eyes from all randomized subjects were included. Not all subjects completed all tests.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Group</title>
            <description>LipiFlow treatment at Pre-operative</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>LipiFlow treatment following 3-month visit</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Refractive Predictability</title>
          <description>Percentage of eyes with achieved manifest refractive spherical equivalence (MRSE) within +/- 0.50 D and +/- 1.00 D.&#xD;
Achieved MRSE for each eye is defined as postoperative MRSE minus targeted MRSE.</description>
          <population>Results from both eyes from all randomized subjects were included. Not all subjects completed all tests.</population>
          <units>Percentage of eyes</units>
          <param>Number</param>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>+/- 0.50 D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.3"/>
                    <measurement group_id="O2" value="82.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>+/- 1.00 D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.0"/>
                    <measurement group_id="O2" value="98.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate of Bothersome Ocular Symptoms</title>
        <description>Patient-Reported Visual Symptom Questionnaire (PRVSQ) Rating Results at 3 months postoperative</description>
        <time_frame>3 months postoperative</time_frame>
        <population>Questionnaires were completed by bilaterally implanted participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Group</title>
            <description>LipiFlow treatment at Pre-operative</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>LipiFlow treatment following 3-month visit</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Bothersome Ocular Symptoms</title>
          <description>Patient-Reported Visual Symptom Questionnaire (PRVSQ) Rating Results at 3 months postoperative</description>
          <population>Questionnaires were completed by bilaterally implanted participants.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Q1a) Halos over the last 7 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q2a) Starburst over the last 7 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q3a) Multiple or Double vision over the last 7 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q4a) Sensitivity to Light over the last 7 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q5a) Glare related to scattered light over the last 7 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q6a) Occlusions over the last 7 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q7a) Poor Low Light Vision over the last 7 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in Total Meibomian Gland Score From Baseline to 1 Month Postoperative</title>
        <description>Total Meibomian Gland Score: Fifteen Meibomian Glands (five temporally, centrally and nasally) in the lower eye are assessed on a scale of 0 - 3 (0 - No secretion, 1 - Inspissated (toothpaste consistency), 2 - Colored/cloudy liquid secretion or 3 - Clear liquid oil secretion). The sum of all 15 glands constitute the total meibomian gland secretion score (range 0-45).</description>
        <time_frame>Preoperative Visit (Baseline) and Postoperative Visit between 30-60 days after cataract surgery on the second eye.</time_frame>
        <population>Results from both eyes from all randomized subjects were included. Not all subjects completed all tests.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Group</title>
            <description>LipiFlow treatment at Pre-operative</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>LipiFlow treatment following 3-month visit</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Total Meibomian Gland Score From Baseline to 1 Month Postoperative</title>
          <description>Total Meibomian Gland Score: Fifteen Meibomian Glands (five temporally, centrally and nasally) in the lower eye are assessed on a scale of 0 - 3 (0 - No secretion, 1 - Inspissated (toothpaste consistency), 2 - Colored/cloudy liquid secretion or 3 - Clear liquid oil secretion). The sum of all 15 glands constitute the total meibomian gland secretion score (range 0-45).</description>
          <population>Results from both eyes from all randomized subjects were included. Not all subjects completed all tests.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="8.2"/>
                    <measurement group_id="O2" value="3.9" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months for study group and 4 months for available control group</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Study Group</title>
          <description>LipiFlow treatment at Pre-operative</description>
        </group>
        <group group_id="E2">
          <title>Control Group</title>
          <description>Prior to LipiFlow treatment at 3-month visit</description>
        </group>
        <group group_id="E3">
          <title>Control Group</title>
          <description>AEs occurring after LipiFlow treatment</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization-ischemic event</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Anterior Capsular Phimosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Cystoid Macular Edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Hospitalization- shingles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hospitalization- fall related to dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hospitalization - Neck procedure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Undesirable Optical Phenomena</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor must review results communication prior to public release and can embargo communications regarding trial results at anytime.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sanjeev Kasthurirangan, PhD</name_or_title>
      <organization>Johnson &amp; Johnson Surgical Vision</organization>
      <phone>+1 408 5335282</phone>
      <email>skasthur@ITS.JNJ.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

